View Older Stories View More Recent Stories

Sep 21, 2017 03:13AM European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Sep 19, 2017 07:00AM Pro Baseball Hall of Famer and Cancer Survivor Mike Schmidt Joins Merck, Jim Kelly and Leading Cancer Organizations To Expand Your Cancer Game Plan To Help More People Impacted by Cancer
Sep 11, 2017 09:02AM Merck (MRK) Says Phase 3 Study of KEYTRUDA Compared to Standard of Care in Patients with Previously Treated HNSCC Didn't Meet Primary Endpoint
Sep 11, 2017 09:00AM Merck Announces Findings from Phase 3 Study of KEYTRUDA® (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcino
Sep 11, 2017 06:57AM Merck KGaA, Darmstadt, Germany, Set to Join Forces with Project Data Sphere to Pioneer Global Oncology Big Data Alliance
Sep 11, 2017 05:48AM Incyte (INCY) Reports Progression-Free Survival Data from ECHO-202 Trial of Epacadostat in Combination with Merck (MRK) KEYTRUDA (pembrolizumab)
Sep 10, 2017 08:45AM Merck’s KEYTRUDA® (pembrolizumab) Continues to Show Overall Survival Benefit Over Chemotherapy with Nearly Two Years Follow-Up in Previously Treated Patients with Advanced Urothelial Carcinoma, Pos
Sep 9, 2017 08:45AM Progression-Free Survival Data from ECHO-202 Trial of Incyte’s Epacadostat in Combination with Merck’s KEYTRUDA® (pembrolizumab) Underscore Durability of Response in Patients with Advanced Melano
Sep 8, 2017 10:36AM Merck (MRK) Reports KEYTRUDA (pembrolizumab) plus Pemetrexed & Carboplatin (pem/carbo) Demonstrated Continued Benefit
Sep 8, 2017 10:33AM Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Carboplatin (pem/carbo) Demonstrated Continued Benefit in Overall Response Rates and Progression-Free Survival Compared to Pem/Carbo Alone in P
Sep 8, 2017 08:04AM Merck (MRK) Says Updated Data for KEYTRUDA in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO
Sep 8, 2017 08:00AM Updated Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Advanced Gastric Cancer Across Treatment Settings to Be Presented at ESMO 2017 Congress
Sep 7, 2017 08:52AM Dr. Sam Bozzette Joins Premier Inc. to Lead Its Research Division
Sep 7, 2017 08:00AM Merck to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
Sep 6, 2017 06:31AM Merck (MRK) to Acquire Rigontec
Sep 6, 2017 06:30AM Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology
Sep 5, 2017 06:31AM Merck (MRK) Says EC Approved KEYTRUDA for Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Sep 5, 2017 06:30AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type of Bladder Cancer
Aug 31, 2017 05:45AM Merck (MRK) Presented New & Updated Data for KEYTRUDA (pembrolizumab) from Extensive Immuno-Oncology Program
Aug 30, 2017 07:22PM New and Updated Data for KEYTRUDA® (pembrolizumab) from Merck’s Extensive Immuno-Oncology Program to be Presented at the ESMO 2017 Congress
Aug 29, 2017 06:16AM Merck (MRK) Reports Results of REVEAL Outcomes Study of Anacetrapib
Aug 29, 2017 02:31AM Merck Announces Results of REVEAL Outcomes Study of Anacetrapib, Investigational Medicine for Cardiovascular Disease
Aug 17, 2017 03:38PM AstraZeneca (AZN), Merck (MRK) Confirm LYNPARZA Received Additional and Broad Approval in U.S. for Ovarian Cancer
Aug 17, 2017 03:36PM LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer
Aug 16, 2017 01:22PM President Trump Announces End of Strategic & Policy Forum and Manufacturing Council on Twitter
Aug 14, 2017 05:11AM Trump yields to pressure, calls neo-Nazis and KKK criminals
Jul 28, 2017 06:45AM Merck Announces Second-Quarter 2017 Financial Results
Jul 27, 2017 09:26AM Pre-Open Stock Movers 07/27: (CAPR) (SHOR) (FB) Higher; (CUR) (AZN) (CYH) Lower (more...)
Jul 27, 2017 09:00AM Mandy Moore and Merck Encourage Women to Plan Ahead in Her Life. Her Adventures. Campaign
Jul 27, 2017 06:45AM REPEAT/AstraZeneca and Merck Establish Strategic Oncology Collaboration
Jul 27, 2017 02:12AM AstraZeneca and Merck Establish Strategic Oncology Collaboration
Jul 25, 2017 03:57PM Merck Announces Fourth-Quarter 2017 Dividend
Jul 25, 2017 08:37AM Merck (MRK) Announces Doravirine Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz in Pivotal Phase 3 Trial for Treatment of HIV-1 Infection
Jul 25, 2017 08:35AM Merck’s Investigational NNRTI, Doravirine, Meets Primary Efficacy Endpoint of Non-Inferiority to Efavirenz, Both in Combination with Other Antiretroviral Agents, in Pivotal Phase 3 Trial for Treatme
Jul 24, 2017 05:04PM Merck (MRK) Says Phase 3 Study of KEYTRUDA Monotherapy in Patients with Previously Treated Recurrent or Metastatic HNSCC Didn't Meet Primary Endpoint
Jul 24, 2017 05:00PM Merck Provides Update on Phase 3 Study of KEYTRUDA® (pembrolizumab) Monotherapy in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Jul 24, 2017 08:05AM Merck (MRK) Announces U.S. Launch of RENFLEXIS
Jul 24, 2017 08:00AM Merck Announces U.S. Launch of RENFLEXIS™ (infliximab-abda), a Biosimilar of Remicade, for All Eligible Indications
Jul 24, 2017 07:05AM Merck (MRK) Announces Week 96 Results from ONCEMRK Study Evaluating ISENTRESS HD
Jul 24, 2017 07:00AM Merck Announces Week 96 Results from ONCEMRK, A Study Evaluating Once-Daily ISENTRESS® HD (raltegravir), in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appro
Jul 21, 2017 07:50AM EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Jul 21, 2017 07:34AM Merck (MRK) Announces EMA's CHMP Recommends Approval for KEYTRUDA for Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma
Jul 21, 2017 07:31AM European Medicines Agency’s CHMP Recommends Approval for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with Locally Advanced or Metastatic Urothelial Carcinoma, a Type o
Jul 20, 2017 03:18PM Merck (MRK) and Pfizer (PFE) Collaborate with Corning (GLW) to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 03:15PM Merck and Pfizer Collaborate with Corning to Modernize Pharmaceutical Glass Packaging
Jul 20, 2017 07:34AM Merck (MRK) Granted Tentative Approval for LUSDUNA Nexvue (insulin glargine injection)
Jul 20, 2017 07:30AM Merck Announces U.S. FDA Grants Tentative Approval for LUSDUNA™ Nexvue™ (insulin glargine injection), a Follow-On Biologic Basal Insulin
Jul 17, 2017 07:07AM Merck (MRK) Announces Presentations of Clinical and Real-World Data AAIC
Jul 17, 2017 07:00AM Merck Announces Presentations of Clinical and Real-World Data at The Alzheimer’s Association International Conference®
Jul 6, 2017 05:45PM Merck to Hold Second-Quarter 2017 Sales and Earnings Conference Call on July 28
View More Recent Stories View Older Stories